# Accurant BioTechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accurant-biotechnology-co

- Industry: Biotechnology
- Headquarters: Ningbo, China
- Website: http://www.accurantbio.com
- Total disclosed funding: $36M
- Latest round: Series B (Jan 29, 2022)
- Investors on record: 7

## About

Established in 2017 and based in Ningbo, China, Accurant Biotech is a laboratory that provides clinical and preclinical macromolecular bioanalysis services. Dr. Xiaoyan Cai, the founder and CEO of the company, served as the global head of WuXi AppTec's macromolecular bioanalysis department and the director of Schering-Plough Biopharmaceutical Analysis Research and Development. The company has labs in Ningbo, Shanghai, New Jersey.

The services of the company can be categorized into four categories which are large molecule bioanalysis, conpanion diagnostic, product release detection and cell line construction. The technology platforms include cell platform, immunization platform, gene platform, cell chamber and BSL-2 laboratory. Bioanalytical services include antibody preparation and cell line construction, covering pharmacokinetics (PK), pharmacodynamics (PD), anti-drug antibody (ADA), neutralizing antibody (NAb), and biomarker  assays. Concomitant diagnostic product development services include LDT methodology development, development and validation, registration testing, clinical trial studies and registration filings of CDx product. The company has cooperation with China Resources Pharmaceutical Group Limited and other enterprises.

The company plans to expand technical service capacity, accelerate the development of concomitant diagnostic product development business, and further strengthen the service capability of providing one-stop technical solutions for testing and analysis for clinical and preclinical studies of biological drugs.

## Funding rounds

- Series B, Jan 29, 2022, $20M — GP Capital, Haibang Venture, Qiaojing Capital, Sherpa Healthcare Partners, GT Capital
- Series A, Jun 10, 2021, $16M — Sherpa Healthcare Partners, GT Capital
- Angel, Jul 5, 2018 — Haibang Venture, Ningbo Science and Technology Financial Service Center
- Angel, Jul 5, 2018 — Haibang Venture, Ningbo Science and Technology Financial Service Center, Yantong Investment

## Investors

- Haibang Venture — Angel, Series B
- Ningbo Science and Technology Financial Service Center — Angel
- Yantong Investment — Angel
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A, Series B
- GT Capital (https://capitalatlas.ai/funds/gt-capital) — Series A, Series B
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series B
- Qiaojing Capital (https://capitalatlas.ai/funds/qiaojing-capital) — Series B